HC Wainwright Has Bearish Forecast for INO Q2 Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Equities researchers at HC Wainwright lowered their Q2 2025 EPS estimates for Inovio Pharmaceuticals in a report issued on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.69) per share for the quarter, down from their prior estimate of ($0.55). HC Wainwright has a “Neutral” rating and a $3.00 price objective on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.49) EPS and FY2025 earnings at ($2.22) EPS.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.23. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.01 million.

Several other research firms have also issued reports on INO. StockNews.com lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. Royal Bank of Canada restated a “sector perform” rating and issued a $5.00 price target on shares of Inovio Pharmaceuticals in a research report on Wednesday. Finally, Oppenheimer reduced their target price on Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $9.75.

Inovio Pharmaceuticals Price Performance

INO opened at $1.95 on Friday. The company has a market capitalization of $71.51 million, a PE ratio of -0.49 and a beta of 1.40. The business has a 50-day moving average of $1.80 and a 200-day moving average of $2.53. Inovio Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $13.44.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nomura Holdings Inc. bought a new stake in Inovio Pharmaceuticals during the 1st quarter worth about $28,000. Alpine Global Management LLC acquired a new stake in shares of Inovio Pharmaceuticals in the fourth quarter valued at approximately $31,000. Freedom Investment Management Inc. bought a new position in Inovio Pharmaceuticals in the 1st quarter worth approximately $31,000. Bank of Montreal Can acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth $43,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth $44,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.